hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
One-place studies are a branch of family history and/or local history with a focus on the entire population of a single road, village or community, not just a single, geographically dispersed family line.
=== West Asia === Documentation of the use of saffron over the span of 3,500 years has been uncovered. Saffron -based pigments have indeed been found in 50,000-year-old depictions of prehistoric places in northwest Iran. The Sumerians later used wild-growing saffron in their remedies and magical potions. It was also known in ancient Egypt, as indicated by a 2000 BC papyrus. Saffron was an article of long-distance trade before the Minoan palace culture's 2nd millennium BC peak. Ancient Persians cultivated Persian saffron (Crocus sativus var. haussknechtii now called Crocus haussknechtii by botanists) in Derbent, Isfahan, and Khorasan by the 10th century BC. At such sites, saffron threads were woven into textiles, ritually offered to divinities, and used in dyes, perfumes, medicines, and body washes. Saffron threads would thus be scattered across beds and mixed into hot teas as a curative for bouts of melancholy. Non-Persians also feared the Persians' usage of saffron as a drugging agent and aphrodisiac. Saffron is featured in trade lists from Mari, Syria, is described in a 7th-century BC Assyrian botanical reference compiled under Ashurbanipal, and is listed among other aromatic plants in the Hebrew Bible, in Song of Songs 4:14. During his Asian campaigns, Alexander the Great used Persian saffron in his infusions, rice, and baths as a curative for battle wounds. Alexander's troops imitated the practice from the Persians and brought saffron-bathing to Greece.
While most historians trace its origins to the period immediately following World War II, others argue that it began with the October Revolution in Russia in 1917 when the Bolsheviks took power. In 1919 Lenin stated that his new state was surrounded by a "hostile capitalist encirclement", and he viewed diplomacy as a weapon that should be used in order to keep the Soviet Union's enemies divided. He began with a new Communist International ("Comintern"), based in Moscow, which was designed to plan for revolutionary upheavals abroad. It was ineffective—Communist uprisings all failed in Germany, Hungary and elsewhere. Historian Max Beloff argues that the Soviets saw "no prospect of permanent peace", with the 1922 Soviet Constitution proclaiming:
==== Satiety ==== As a peptide hormone, CCK mediates satiety by acting on the CCK receptors distributed widely throughout the central nervous system. The mechanism for hunger suppression is thought to be a decrease in the rate of gastric emptying. CCK also has stimulatory effects on the vagus nerve, effects that can be inhibited by capsaicin. The stimulatory effects of CCK oppose those of ghrelin, which has been shown to inhibit the vagus nerve. The effects of CCK vary between individuals. For example, in rats, CCK administration significantly reduces hunger in adult males, but is slightly less effective in younger subjects, and even slightly less effective in females. The hunger-suppressive effects of CCK also are reduced in obese rats.
=== Progesterone === Progesterone is a naturally occurring steroid hormone and is used in hormone therapy and birth control pills, among other applications. There are two known forms of naturally occurring progesterone (or nat‐progesterone), and other synthetic polymorphs of the hormone have also been created and studied. Early scientists reported being able to crystallize both Form 1 and Form 2 of nat‐progesterone, and they could convert Form 2 into Form 1, which has higher melting point (129–131 °C instead of 121–123 °C), and is more thermodynamically stable by heat capacity experiments. When later scientists tried to crystallize Form 2 from pure materials, they could not. Attempts to replicate older instructions (and variations on those instructions) for crystallization of Form 2 invariably produced Form 1 instead, sometimes even leading to crystals of exceptional purity but still of Form 1. Researchers have tentatively suggested that Form 2 became harder to produce already by 1975, based on a review of production difficulties documented or alluded to in existing literature. Form 2 was eventually successfully synthesized by using pregnenolone, a structurally similar compound, as an additive in the crystallization process. The additive seemed to reverse the order of stability of the polymorphs.
Sources: en.wikipedia.org
=== Characteristics in patients === There is a relationship between the subcutaneous dose of calcitonin and peak plasma concentrations. Following parenteral administration of 100 IU calcitonin, peak plasma concentration lies between about 200 and 400 pg/ml. Higher blood levels may be associated with increased incidence of nausea, vomiting, and secretory diarrhea.
CYP2D6 for which it is both a substrate and a potent inhibitor. CYP2B6 (strong) inhibitor. CYP3A4 (weak) inhibitor. CYP1A2 (weak) inhibitor. CYP2C9 (weak) inhibitor. CYP2C19 (weak) inhibitor. Paroxetine has been shown to be an inhibitor of G protein-coupled receptor kinase 2 (GRK2).
An amino acid neurotransmitter is an amino acid which is able to transmit a nerve message across a synapse. Neurotransmitters (chemicals) are packaged into vesicles that cluster beneath the axon terminal membrane on the presynaptic side of a synapse in a process called endocytosis. Amino acid neurotransmitter release (exocytosis) is dependent upon calcium Ca2+ and is a presynaptic response.
Coronary occlusion is caused by the buildup of fats, cholesterol and other substances in and on the walls of the hearts arteries. As plaque builds up, the arteries narrow. Plaque often starts building up during childhood and is heavily influenced by genetics, but also lifestyle and high blood cholesterol. This condition is referred to as atherosclerosis. The buildup on the walls of the hearts arteries is referred to as plaque. Plaque causes arteries to narrow and block blood flow. Conditions that aid in the development of coronary artery disease are diabetes or insulin resistance, high blood pressure, sedentary lifestyle, and smoking or tobacco use. Risk Factors that are not controllable are age, birth sex, and family history. Getting older increases the risk of damaged and narrowed arteries. Men are at a greater risk of coronary artery disease, with women's risk increasing after menopause.
== Drug interactions == Thiotepa can have various interactions with other medications or therapies that can impact patient safety and treatment efficacy. Aprepitant, a drug that prevents nausea and vomiting that may occur during chemotherapy, inhibits CYP-enzymes, which decrease the metabolism of thiotepa to tepa. Its importance is relatively minor because inhibition itself is small and due to the variability of thiotepa clearance in different individuals. The anti-seizure medication phenytoin induces the CYP3A4 enzyme. This leads to an increased rate of tepa formation from thiotepa, which highly influences its clearance and concentration. Higher local concentrations of the more reactive tepa can potentially induce hepatotoxicity. Additionally, cytotoxic drugs such as thiotepa can reduce the absorption of phenytoin leading to the increased risk of seizures. It is advised to avoid the use of both drugs simultaneously or decrease thiotepa doses. Myelosuppressive/myelotoxic agents such as melphalan, busulfan, treosulfan, and cyclophosphamide, as well as the concurrent use of thiotepa, may increase the risk of hematologic adverse reactions and pulmonary toxicity, as they share similar toxicity profiles. Additionally, the use of live attenuated vaccines (including yellow fever) poses a risk of systemic and potentially fatal infection, with the risk further heightened in patients who are already immunosuppressed due to their underlying disease.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.